Investor Presentation by Morphic Medical Inc
Crystal Amber Fund Limited announced that Morphic Medical Inc. (MMI), in which the Fund holds a 96.7% stake of the issued share capital, will host a live investor presentation followed by a Q&A session on October 16, 2025, at 10:30 am. The presentation, hosted by MMI's CEO Mike Gutteridge, will include opening remarks from Crystal Amber's Chairman, Chris Waldron. The presentation is accessible to existing and potential shareholders via the Investor Meet Company platform, where questions can be submitted. No new material information will be disclosed during the event, and the presentation slides will be available on morphicmedical.com.
Select text to share a quote on X · sign in to keep highlights & notes in your CRS notes
The Board of Crystal Amber is pleased to announce that Morphic Medical Inc. ("MMI"), the medical device company in which the Fund owns 96.7% of the issued share capital, will be conducting a live investor presentation this morning via the Investor Meet Company platform, followed immediately by a Q&A session.
This online event will take place at 10:30am today (Thursday 16 October 2025).
The presentation will be hosted by Mike Gutteridge, MMI's CEO and President, with opening remarks from Chris Waldron, Crystal Amber's Chairman.
To register, please visit: https://www.investormeetcompany.com/crystal-amber-fund-limited/register-investor
Investors who already follow CRYSTAL AMBER FUND LIMITED on the Investor Meet Company platform will automatically be invited.
No new material information will be disclosed during the event. The slides of the presentation will subsequently be made available on morphicmedical.com.
Morphic Medical is the developer of RESET®, the first incision-free, endoscopically delivered therapy designed to treat obesity and related metabolic disorders such as type 2 diabetes.
RESET is a duodenal-jejunal bypass liner (DJBL) that is implanted and removed endoscopically, remaining in place for up to nine months. By creating a temporary barrier in the upper intestine, it has been shown to support significant weight loss and improved blood sugar control by enhancing natural gut hormone responses, in a way similar to GLP-1 therapies. Unlike gastric bypass surgery, RESET is minimally invasive and fully reversible.
RESET addresses a major global health need, with an estimated 93 million adults in Europe alone living with obesity and type 2 diabetes. It has been endorsed in the latest clinical guidelines for obesity treatment by both the European Society for Gastrointestinal Endoscopy (ESGE) and the American Society for Gastrointestinal Endoscopy (ASGE) - a strong validation from the medical community.
Founded in 2003, Morphic Medical is headquartered in Boston, Massachusetts.
For more information, please visit morphicmedical.com or follow on X (formerly Twitter) and / or LinkedIn.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.